FEBRUARY 21, 2019
August 17, 2018
Aetna considers the measurement of exhaled nitric oxide medically necessary for evaluation of #asthma and for monitoring response to long-term control therapy in members aged 5 years and older.
December 11, 2017
Spirosure Makes FDA 510(k) Submission for Clearance to Sell Fenom PRO™ Point-of-Care Breathalyzer in the U.S.
CE mark already in place for portable analyzer that helps patients manage their asthma by measuring nitric oxide (NO) in their exhaled breath, a biomarker foreshadowing airway obstruction
November 2, 2017
NTK Sensor Power Fenom PRO
Nagoya, November 2, 2017―NGK SPARK PLUG CO., LTD. (Chairman, President, and CEO: Shinichi Odo, Headquarters: Nagoya, hereafter NTK) is pleased to announce that its sensing unit has been adopted to an exhaled nitric oxide (NO) measuring instrument and will be distributed in Europe starting on November 20, 2017.
August 3, 2016
Commercialization to start soon for company’s initial product, Fenom PRO™, a point-of-care portable breath analyzer that measures nitric oxide in exhaled breath, a biomarker that foreshadows airway obstruction
JUNE 30, 2016
Funding will drive commercialization of the company’s initial product, Fenom PRO™, a point-of-care portable breath analyzer that measures nitric oxide in exhaled breath, a biomarker that foreshadows airway obstruction
FEBURARY 9, 2016
JULY 17, 2015
SPIROMETRIX RECEIVES ISO 13485 CERTIFICATION
NOVEMBER 7, 2014
SPIROMETRIX CLOSES $8.6 MILLION SERIES B FINANCING
Spirometrix announced today the closing of an $8.6 million Series B Preferred Stock financing. The financing was led by biosensor manufacturing partner NGK SPARK PLUG CO., LTD (hereafter NTK), which invested approximately $5 million, and also included current investor Simul Investments. As part of the financing, a member of NTK will join the Board of Directors of Spirometrix.